See more : Alpha Wastewater, Inc. (AWWI) Income Statement Analysis – Financial Results
Complete financial analysis of Hepion Pharmaceuticals, Inc. (HEPA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hepion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Prodigy Gold NL (PRX.AX) Income Statement Analysis – Financial Results
- Guangdong AVCiT Technology Holding Co., Ltd. (001229.SZ) Income Statement Analysis – Financial Results
- Beam Global (BEEMW) Income Statement Analysis – Financial Results
- Collective Mining Ltd. (CNL.V) Income Statement Analysis – Financial Results
- Lucky Friday Extn Mining Co. (LFEX) Income Statement Analysis – Financial Results
Hepion Pharmaceuticals, Inc. (HEPA)
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 0.00 | 21.53K | 16.36K | 0.00 | 0.00 |
| Gross Profit | -67.13K | -77.46K | -86.07K | -34.52K | -26.74K | -18.79K | -21.94K | 0.00 | -21.53K | -16.36K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.64M | 33.27M | 20.40M | 12.00M | 3.18M | 7.59M | 14.33M | 13.65M | 15.02M | 8.40M | 314.25K | 734.56K |
| General & Administrative | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 7.28M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -583.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 6.69M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Other Expenses | 3.19M | 0.00 | 0.00 | 0.00 | -179.65K | -108.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.02M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Cost & Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.04M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.47K | 10.16K | 8.86K | 31.23K | 555.00K | 339.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 27.99K | 21.53K | 16.36K | 1.32K | 841.00K |
| EBITDA | -49.26M | -43.54M | -30.32M | -20.11M | -7.74M | -14.58M | -20.62M | -21.02M | -20.81M | -13.94M | -1.67M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.45M | -45.49M | -30.40M | -20.15M | -7.77M | -14.59M | -21.04M | -21.02M | -20.81M | -13.96M | -1.67M | -841.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -887.11K | 404.83K | -2.32M | -177.28K | -175.94K | 4.61M | 2.13M | 4.22M | 3.81M | -387.90K | -3.61M | -1.97K |
| Income Before Tax | -49.34M | -45.08M | -32.72M | -20.32M | -7.95M | -9.99M | -18.92M | -16.80M | -17.00M | -14.35M | -5.28M | -842.97K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 409.02K | -2.88M | 8.86K | 30.58K | -908.68K | -536.00K | -3.90M | -1.91M | -3.81M | 387.90K | 3.61M | -1.97K |
| Net Income | -48.93M | -42.20M | -32.72M | -20.35M | -7.04M | -9.45M | -15.02M | -14.89M | -17.00M | -14.35M | -5.28M | -842.97K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| EPS Diluted | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| Weighted Avg Shares Out | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.20K | 2.42K | 1.94K | 1.14K | 33.00K |
| Weighted Avg Shares Out (Dil) | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.21K | 2.42K | 1.94K | 1.14K | 33.00K |
4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%
These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Hepion Pharmaceuticals is a promising candidate in the race for an effective drug for treating NASH. Although still in a very early phase of trials, CRV431 has presented very promising preclinical results.
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the postponement of...
Hepion Pharma's NASH Candidate Aces Mid-Stage Study
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced positive topline results from its Phase 2a AMBITION NASH clinical trial evaluating CRV431, a potent inhibitor of cyclophilins. In the trial, CRV431 blood concentrations after oral dosing of either 75 mg or 225 mg once daily...
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that its 2021...
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
EDISON, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, is pleased to announce...
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it has...
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, announced that...
HEPA Stock Price Increases Over 5% Pre-Market: Why It Happened
The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) increased by over 5% pre-market. This is why it happened.
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's Lead Drug, CRV431
EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced...
Source: https://incomestatements.info
Category: Stock Reports